These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 24242757)
1. Molecular analysis of diffuse intrinsic brainstem gliomas in adults. Reyes-Botero G; Giry M; Mokhtari K; Labussière M; Idbaih A; Delattre JY; Laigle-Donadey F; Sanson M J Neurooncol; 2014 Jan; 116(2):405-11. PubMed ID: 24242757 [TBL] [Abstract][Full Text] [Related]
2. Molecular Characteristics of Thalamic Gliomas in Adults. Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385 [TBL] [Abstract][Full Text] [Related]
3. Picca A; Berzero G; Bielle F; Touat M; Savatovsky J; Polivka M; Trisolini E; Meunier S; Schmitt Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Di Stefano AL; Sanson M Neurology; 2018 Jun; 90(23):e2086-e2094. PubMed ID: 29728520 [TBL] [Abstract][Full Text] [Related]
4. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842 [TBL] [Abstract][Full Text] [Related]
5. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000 [TBL] [Abstract][Full Text] [Related]
9. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Houillier C; Wang X; Kaloshi G; Mokhtari K; Guillevin R; Laffaire J; Paris S; Boisselier B; Idbaih A; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY Neurology; 2010 Oct; 75(17):1560-6. PubMed ID: 20975057 [TBL] [Abstract][Full Text] [Related]
10. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases. Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795 [TBL] [Abstract][Full Text] [Related]
11. Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations. Tauziède-Espariat A; Saffroy R; Pagès M; Pallud J; Legrand L; Besnard A; Lacombe J; Lot G; Borha A; Tazi S; Adle-Biassette H; Polivka M; Lechapt E; Varlet P Clin Neuropathol; 2018; 37(5):209-216. PubMed ID: 29809131 [TBL] [Abstract][Full Text] [Related]
12. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441 [TBL] [Abstract][Full Text] [Related]
13. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions. Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917 [TBL] [Abstract][Full Text] [Related]
15. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324 [TBL] [Abstract][Full Text] [Related]
16. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation. Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694 [TBL] [Abstract][Full Text] [Related]
17. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas. Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718 [TBL] [Abstract][Full Text] [Related]
18. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
19. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788 [TBL] [Abstract][Full Text] [Related]
20. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas. Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]